Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The search for the ideal positive inotropic agent.

× No keyword cloud information.

17 in total

Review 1. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.

Authors: Johanna Hummel; Gerta Rücker; Brigitte Stiller
Journal: Cochrane Database Syst Rev Date: 2017-08-02

2. Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension.

Authors: Pablo Lobo Martínez; Ignacio Oulego Erroz; Sandra Gautreux Minaya; Luis Miguel Rodríguez Fernández
Journal: Pediatr Cardiol Date: 2011-07-10 Impact factor: 1.655

3. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis.

Authors: P Nony; J P Boissel; M Lievre; A Leizorovicz; M C Haugh; S Fareh; B de Breyne
Journal: Eur J Clin Pharmacol Date: 1994 Impact factor: 2.953

Review 4. Medical treatment beyond ACE inhibition: false promise or lack of vision?

Authors: J T Walsh; A J Cowley
Journal: Br Heart J Date: 1994-09

5. Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting.

Authors: Cuneyt Eris; Senol Yavuz; Faruk Toktas; Tamer Turk; Arif Gucu; Burak Erdolu; M Tugrul Goncu
Journal: Int J Clin Exp Med Date: 2014-01-15

Review 6. [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

Authors: S Rehberg; C Ertmer; H Van Aken; M Lange; K Bröking; A Morelli; M Westphal
Journal: Anaesthesist Date: 2007-01 Impact factor: 1.041

7. Congestive heart failure revisited: new concepts in treatment.

Authors: L J Haywood
Journal: J Natl Med Assoc Date: 1996-08 Impact factor: 1.798

Review 8. Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors: J Tauke; D Han; M Gheorghiade
Journal: Cardiovasc Drugs Ther Date: 1994-10 Impact factor: 3.727

9. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

Authors: S Matsui; A Matsumori; Y Matoba; A Uchida; S Sasayama
Journal: J Clin Invest Date: 1994-09 Impact factor: 14.808

10. Pharmaceutical management of decompensated heart failure syndrome in children: current state of the art and a new approach.

Authors: Avihu Z Gazit; Phineas P Oren
Journal: Curr Treat Options Cardiovasc Med Date: 2009-10